A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivoFibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradationApplication of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signalingPositional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinomaSHARPIN is an endogenous inhibitor of β1-integrin activationCandidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarraysDetection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridizationInternational network of cancer genome projects.ANX7, a candidate tumor suppressor gene for prostate cancerExpression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcomePlasticity of blood- and lymphatic endothelial cells and marker identificationA comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responsesAxitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationSomatic STAT3 mutations in large granular lymphocytic leukemiaLoss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breastELAC2/HPC2 involvement in hereditary and sporadic prostate cancerAIB1, a steroid receptor coactivator amplified in breast and ovarian cancerc-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cellsNovel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changesNovel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectivelyIndependent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancerMajor susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide searchA missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in FinlandTissue microarrays for rapid linking of molecular changes to clinical endpointsAnalysis of kinase gene expression patterns across 5681 human tissue samples reveals functional genomic taxonomy of the kinomeGTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasetsHigh-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerChemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cellsSystemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcomaHigh-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cellsProtein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell linesmiRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumorsTissue microarrays for high-throughput molecular profiling of tumor specimensComparative genomic hybridization for molecular cytogenetic analysis of solid tumorsAkt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaRelevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data.A community effort to assess and improve drug sensitivity prediction algorithms.Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.
P50
Q22010817-947C9DFF-BDF6-4FA3-9648-993B3EC9AD9DQ24301346-F0D52CFC-54D3-4AED-B701-3B8AA32F3F9EQ24309408-47B904B9-29A5-4023-B983-76CC741F9A67Q24317037-89A5286E-38E7-4E51-A1D9-A1E52FF14BE1Q24338618-1EE4A704-C363-49F1-B2AB-33D95D4D6A0BQ24550972-24694591-E729-47B0-B613-04AB9932DF52Q24564349-7BA344D1-8688-40FD-9EF9-A0D8B65B540AQ24611474-EEF2BBB0-6FAB-41DC-99B9-9AE9E2B6D7FEQ24635232-4E173E67-16FA-4953-AB5A-515CCC8750FBQ24684801-C3B1E127-2E44-46AA-A696-6354FAB190F0Q27306942-4C43C62D-52DE-477F-AB0F-E276BEA99DDAQ27329871-132FC625-EC81-4917-8618-388B8944BD79Q27698001-2A712BFF-A776-4DD5-8511-83C5427C2375Q27851792-46854A73-3DB6-4C81-9CD5-DBA87D748FB8Q28188395-2FBFDCB6-DACA-4E4A-B684-6DF8A61C2E46Q28212948-0EBFFC2E-534B-47DF-99A9-95CCA4AFFB24Q28245902-A2FDF2D1-B674-4AFB-873C-469B36A9F573Q28270073-B1E9AF44-3042-4B2A-A91F-DF9ED30D89CFQ28278756-0DCFD39F-63C8-4C7C-9C35-FCC8F45FE78FQ28280796-12C53878-DE38-4694-9B79-DDA166C83DF5Q28287018-539C872C-B94D-4C8B-8480-89123F49D22BQ28296089-147CA69D-B0E7-4B68-86EA-596F9A6F35CBQ28365264-F4A9144D-E775-4722-884E-A849F8EECD00Q28365753-CC29B935-E44E-48FE-A303-49DC209F98CAQ28476427-83EEBDA6-4469-4ADB-8979-0C985B3ED542Q28477216-9AF87089-DCF8-41C3-8AE9-E97B725A87F3Q28480861-2BF9C41A-84F5-4DB3-9F9F-5138E7D6545EQ28484299-A653A80F-2CC9-4846-A038-8E8210459CFBQ28485467-EE664CF6-572A-4159-BCBA-5A70981F9F25Q28534624-2ACB917F-4991-4C1C-8380-7A983767A2CBQ28651483-2DB3BA28-0BB6-4D12-A967-BA3E4396ECBEQ28742532-FBDD9189-BA73-466B-B754-FFA41F0735DAQ29618675-E53AFE62-16C1-41D1-AC3B-52D5C901F6FDQ29618818-3C51F3C6-6B0C-452D-9A07-77E5221424B5Q30361598-F70320D1-1E92-475B-879C-2A562D6BDB3FQ30365752-1F0C9682-4401-429D-96D2-D692061613A8Q30368859-3ED9C335-6427-41EB-B7EE-AF69CDC986BBQ30371323-FADB671C-610C-49DF-92B5-ABA440E405A5Q30436867-E64B96B0-0F0E-426B-A873-253D169AFEB7Q30438661-4363DA26-3D7E-452A-B3CF-8044836DB778
P50
description
Finnish professor of molecular ...... professor (Academy of Finland)
@en
Fins onderzoeker (1960-)
@nl
Professor i precisionsmedicin vid Karolinska Institutet
@sv
finnischer Forscher
@de
investigador finlandés
@ast
investigador finlandés
@es
suomalainen molekyylilääketiet ...... iaprofessori (Suomen Akatemia)
@fi
name
Olli-Pekka Kallioniemi
@ast
Olli-Pekka Kallioniemi
@ca
Olli-Pekka Kallioniemi
@da
Olli-Pekka Kallioniemi
@en
Olli-Pekka Kallioniemi
@es
Olli-Pekka Kallioniemi
@fi
Olli-Pekka Kallioniemi
@fo
Olli-Pekka Kallioniemi
@fr
Olli-Pekka Kallioniemi
@ga
Olli-Pekka Kallioniemi
@is
type
label
Olli-Pekka Kallioniemi
@ast
Olli-Pekka Kallioniemi
@ca
Olli-Pekka Kallioniemi
@da
Olli-Pekka Kallioniemi
@en
Olli-Pekka Kallioniemi
@es
Olli-Pekka Kallioniemi
@fi
Olli-Pekka Kallioniemi
@fo
Olli-Pekka Kallioniemi
@fr
Olli-Pekka Kallioniemi
@ga
Olli-Pekka Kallioniemi
@is
altLabel
Kallioniemi, O.
@en
Kallioniemi, O.-P.
@en
Kallioniemi, Olli P.
@en
Kallioniemi, Olli
@en
Kallioniemi, Olli-Pekka
@en
prefLabel
Olli-Pekka Kallioniemi
@ast
Olli-Pekka Kallioniemi
@ca
Olli-Pekka Kallioniemi
@da
Olli-Pekka Kallioniemi
@en
Olli-Pekka Kallioniemi
@es
Olli-Pekka Kallioniemi
@fi
Olli-Pekka Kallioniemi
@fo
Olli-Pekka Kallioniemi
@fr
Olli-Pekka Kallioniemi
@ga
Olli-Pekka Kallioniemi
@is
P214
P244
P1053
H-5111-2011
P106
P1651
88YKKfzkPuk
P19
P21
P213
0000 0000 2797 4033
P214
P244
P2456
P27
P31
P496
0000-0002-3231-0332
P569
1960-11-20T00:00:00Z
P734
P735
P7859
lccn-n00121053